Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx

Christopher G Youn; Joo Yeon Kim; Vivian B Yang; Gordon H Bae

doi:10.2196/64300

Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx

JMIR Dermatol. 2024 Dec 13:7:e64300. doi: 10.2196/64300.

Authors

Christopher G Youn¹, Joo Yeon Kim¹, Vivian B Yang², Gordon H Bae¹

Affiliations

¹ Department of Dermatology, Stanford University School of Dermatology, 450 Broadway, Pavilion C, 2nd Floor, Redwood City, CA, 94063, United States, 1 650-721-7190.
² School of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA, United States.

PMID: 39671560
PMCID: PMC11661688
DOI: 10.2196/64300

Abstract

This observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.

Keywords: US; United States; affordability; burden; convenience; cost; dermatologic; dermatology; drug company; financial burden; financial distress; health outcomes; medication; pharmaceutical; pharmacist; pharmacy; prescription.

Publication types

Observational Study
Comparative Study

MeSH terms

Cost Savings*
Cuba
Dermatology* / economics
Drug Costs
Drug Industry / economics
Humans